Is Thymosin Alpha-1 Legal in Louisiana?
HealthRX.com
Federally, thymosin alpha-1 has no US approval
At a glance
- FDA approval / Not approved; four US orphan drug designations are not approvals [1]
- Pharmacy bulk-substance list / FDA proposed not to add it; committee voted 17 no, 4 yes [3]
- State-licensed pharmacy list / In none of the three categories [2]
- Outsourcing facility list / Category 3, nominated without adequate support [4]
- Category 1 policy / Does not apply to thymosin alpha-1 [2]
- Safety-risk table / Moved to 'nominated but withdrawn'; FDA concerns remain posted [5]
- HHS peptide policy / Not one of the six peptides in the October 2026 draft [6]
- Approved outside the US / Italy, India, Hong Kong [1]
Is thymosin alpha-1 FDA-approved?
No. A Drugs@FDA search found no US application for it [1]. FDA's December 2024 review notes four US orphan drug designations, but orphan designation is a separate process from approval and is not an approval [1]. Zadaxin is the brand of the finished 1.6 mg injection sold outside the US; it is not interchangeable with bulk thymosin alpha-1 powder [1].
Can a US pharmacy compound it?
On FDA's list for state-licensed pharmacies and physicians, updated May 14, 2026, thymosin alpha-1 appears in none of the three categories [2]. On the separate list for outsourcing facilities, updated March 21, 2025, it is in category 3, 'nominated without adequate support' [4]. FDA's category 1 policy, under which the agency generally takes no action against compounders that meet its conditions, does not apply to it [2].
FDA proposed that the peptide not be added to the pharmacy bulk-substance list. On December 4, 2024 the Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate; members who voted no cited no compelling evidence of clinical effectiveness and safety, and some who voted yes said patients should have access [3]. It had been in category 2 (significant safety risks) and came off that list when the nominators withdrew, but FDA's concerns remain posted: significant risk of immunogenicity for certain routes of administration, peptide impurity and characterization problems, and safety information inadequate for the agency to understand the extent of any safety issues [5]. It is also not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy, and no FDA or HHS action allowing its compounding is known [6].
What this means for Louisiana
The federal record covers FDA approval and compounding policy only. Whether a Louisiana pharmacy may compound thymosin alpha-1, or a Louisiana prescriber may order it, depends on state law that is not covered here.
Questions worth asking
Where is it approved, and is there a US dose?
FDA lists Italy, where Zadaxin is authorized as an adjuvant to influenza vaccination in immunocompromised people; India, for chronic hepatitis B in adults 18 or older with compensated liver disease and virus replication; and Hong Kong [1]. The European Medicines Agency holds only an orphan designation for hepatocellular carcinoma, which is not a marketing approval [1].
No US-approved dose exists [1]. The Italian Zadaxin label gives 1.6 mg subcutaneously or intramuscularly twice weekly for 4 weeks starting at the first vaccination, repeated from week 8 to week 12 at the second vaccination [1].
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Frequently asked questions
Is thymosin alpha-1 legal in Louisiana?
Is thymosin alpha-1 FDA-approved?
Why did FDA propose not to add it to the pharmacy bulk-substance list?
Can a compounding pharmacy make thymosin alpha-1 under FDA's lists?
What dose is approved in the US?
References